Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
MPM Capital
company
About
MPM Capital is an investment firm that invests in early-stage companies developing innovative therapeutic technologies in oncology.
- 11 - 50
Highlights
Details
- Industries
- Biotechnology,Health Care,Life Science,Venture Capital
- Founded date
- Jan 1, 1996
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Investor Type
- PE,Venture Capital
MPM Capital is a healthcare investment firm that invests in early-stage companies developing innovative therapeutic technologies in oncology. The firm is founding and investing in life sciences companies both public and private that seek to cure major diseases by translating scientific innovations into positive clinical outcomes.
Investments
Number of Investments
Number of Lead Investments
14
3
MPM Capital has made 14 investments. Their most recent investment was on
Oct 21, 2021, when ReCode Therapeutics raised $210M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 21, 2021
ReCode Therapeutics
|
Series B | $210M | Biopharma | — |
|
Oct 19, 2021
Protego Biopharma
|
Series A | $51.04M | Biopharma | Yes |
|
Mar 31, 2021
Entrada Therapeutics
|
Series B | $116M | Biotechnology | — |
|
Mar 26, 2020
ReCode Therapeutics
|
Series A | $80M | Biopharma | — |
|
Dec 18, 2018
Entrada Therapeutics
|
Series A | $59M | Biotechnology | Yes |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
